Prevesh Rustagi, MD
Psychiatry · Fort Wayne, INNPI 1245237411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,220 of the $63,524 with a category attached, or 66.5%. 33 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 41.3% of the total. Reporting peaked in 2024 at $21,072 and has fallen 89.1% since, to $2,305 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 768 payments — averaging $82.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$26K
- Teva Pharmaceuticals USA, Inc.$15K
- Ironshore Pharmaceuticals Inc.$11K
- Lundbeck LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$989
- Corium, LLC$870
- plus $7K from 27 others
What the payments were for
- Consulting fees$4,0006%
- Speaking & faculty fees$42,22066%
- Travel & lodging$2,4774%
- Food & beverage$14,67523%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 79 | $26,260 |
| Teva Pharmaceuticals USA, Inc. | 57 | $15,070 |
| Ironshore Pharmaceuticals Inc. | 64 | $10,943 |
| Lundbeck LLC | 105 | $2,099 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $989 |
| Corium, LLC | 43 | $870 |
| Otsuka America Pharmaceutical, Inc. | 37 | $846 |
| AbbVie(2 entities) | 41 | $720 |
| Neurocrine Biosciences, Inc. | 33 | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $703 |
| Alkermes, Inc. | 29 | $614 |
| Neos Therapeutics, LP | 28 | $541 |
| Adlon Therapeutics L.p. | 26 | $465 |
| Tris Pharma Inc | 29 | $463 |
| Noven Therapeutics, LLC | 15 | $274 |
| Idorsia Pharmaceuticals US Inc | 12 | $217 |
| Collegium Pharmaceutical, Inc. | 11 | $207 |
| Axsome Therapeutics, Inc. | 10 | $199 |
| Vanda Pharmaceuticals Inc. | 13 | $195 |
| Eisai Inc. | 11 | $189 |
| E.r. Squibb & Sons, L.L.C. | 6 | $131 |
| Bausch Health US, LLC | 8 | $119 |
| Jazz Pharmaceuticals Inc. | 6 | $95 |
| Shire North American Group Inc | 5 | $90 |
| AstraZeneca | 1 | $88 |
| Harmony Biosciences LLC | 4 | $82 |
| Merck | 5 | $75 |
| Vertical Pharmaceuticals, LLC | 4 | $59 |
| Almatica Pharma LLC | 3 | $55 |
| Johnson & Johnson | 3 | $51 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| OWP Pharmaceuticals, Inc. | 2 | $38 |
| Neuronetics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$24,914
- UZEDY$13,894
- JORNAY PM$5,740
- Jornay PM 20mg capsules (Bottle of 100)$4,191
- REXULTI$121
How this compares
$63,524 in reported general payments places this provider in the 95th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $118,247 |
| TrintellixVortioxetine Hydrobromide | 46 | $20,328 |
| Aripiprazole | 125 | $10,145 |
| VraylarCariprazine Hcl | 12 | $8,357 |
| Olanzapine | 166 | $7,829 |
| Duloxetine Hcl | 246 | $6,842 |
| Clozapine | 67 | $5,849 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,686 |
| Buspirone Hcl | 213 | $4,510 |
| Atomoxetine Hcl | 30 | $4,489 |
| Trazodone Hcl | 394 | $4,198 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $4,095 |
| Quetiapine Fumarate | 190 | $4,073 |
| Tranylcypromine Sulfate | 17 | $4,065 |
| Divalproex Sodium | 95 | $3,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $719 | $118,24715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $703 | $25,01358 claims |
| AbbVieVraylar | $720 | $8,35712 claims |
| Almatica Pharma LLCSertraline Hcl | $55 | $2,218224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Fort Wayne
- Larry LambertsonFort Wayne$208K
- Mahender SurakantiFort Wayne$13K
- Geeta BishtFort Wayne$11K
- Andrea NaaumFort Wayne$8K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.